Pharmacogenetics of etanercept: Role of TNF-α gene polymorphisms in improving its efficacy

Expert Opinion on Drug Metabolism and Toxicology

Volumn 10, Issue 12, 2014, Pages 1703-1710

  Murdaca, Giuseppe ^a   Spanò, Francesca ^a   Contatore, Miriam ^a   Guastalla, Andrea ^a   Magnani, Ottavia ^a   Puppo, Francesco ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Etanercept; Immune mediated diseases; TNF gene polymorphisms; TNF inhibitors

Indexed keywords

ETANERCEPT; FC RECEPTOR; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA DRB1 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR 1; ANTIINFLAMMATORY AGENT; IMMUNOGLOBULIN G; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ALLELE; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; GENOTYPE; HEREDITY; HUMAN; PHARMACOGENETICS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; GENETICS; PATIENT SELECTION; PERSONALIZED MEDICINE; PHENOTYPE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; HUMANS; IMMUNOGLOBULIN G; INDIVIDUALIZED MEDICINE; PATIENT SELECTION; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84911407518     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2014.970165     Document Type: Review

References (75)

1. Murdaca G, Colombo BM, Puppo F. Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events. Int J Immunopathol Pharmacol 2009;22(3):557-65
2. Murdaca G, Colombo BM, Cagnati P, et al. Update upon efficacy and safety of TNF-alpha inhibitors. Expert Opin Drug Saf 2012;11(1):1-5
3. Murdaca G, Colombo BM, Puppo F. Emerging biological drugs: a new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events. Autoimmun Rev 2011;11(1):56-60
4. Murdaca G, Colombo BM, Puppo F. Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications. Drugs Today (Barc) 2011;47(4):277-88
5. Murdaca G, Colombo BM, Barabino G, et al. Anti-tumor necrosis factor-alpha treatment with infliximab for disseminated granuloma annulare. Am J Clin Dermatol 2010;11(6):437-9
6. Puppo F, Murdaca G, Ghio M, Indiveri F. Emerging biologic drugs for the treatment of rheumatoid arthritis. Autoimmun Rev 2005;4(8):537-41
7. Murdaca G, Spanò F, Puppo F. Selective TNF-alpha inhibitor-induced injection site reactions. Expert Opin Drug Saf 2013;12(2):187-93
8. Murdaca G, Spanò F, Puppo F. Use of leflunomide plus TNF-alpha inhibitors in rheumatoid arthritis. Expert Opin Drug Saf 2013;12(6):801-4
9. Murdaca G, Spanò F, Puppo F. Long term treatment of rheumatoid arthritis with adalimumab. Open Access Rheumatol Res Rev 2013;5:43-9
10. Murdaca G, Spanò F, Puppo F. Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety. Expert Opin Drug Saf 2014;13(3):295-305
11. Murdaca G, Spanò F, Contatore M, et al. The potential use of TNF-alpha inhibitors in systemic sclerosis. Immunotherapy 2014;6(3):283-9
12. Murdaca G, Spanò F, Contatore M, et al. Efficacy and safety of etanercept in chronic immune-mediated disease. Expert Opin Drug Saf 2014;13(5):649-61
13. Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666-70
14. Hehlgans T, Pfeer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 2005;115:1-20
15. Taylor PC. Antibody therapy for rheumatoid arthritis. Curr Opin Pharmacol 2003;3:323-8
16. Chang J, Girgis L. Clinical use of anti-TNF-alpha biological agents-a guide for GPs. Aust Fam Physician 2007;36:1035-8
17. Hochberg MC, Lebwohl MG, Plevy SE, et al. The benefit/risk profile of TNFblocking agents: findings of a consensus panel. Semin Arthritis Rheum 2005;34:819-36
18. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis 2005;64(Suppl 4):iv2-14
19. Gisondi P, Girolomoni G. Biologic therapies in psoriasis: a new therapeutic approach. Autoimmun Rev 2007;6:515-19
20. Kyle S, Chandler D, Griffiths CEM, et al. Guideline for anti-TNF-alpha therapy in psoriatic arthritis. Rheumatology 2005;44:390-7
21. Murdaca G, Colombo BM, Contini P, Puppo F. Determination of lymphotoxin-alpha levels in patients with psoriatic arthritis undergoing etanercept treatment. J Interferon Cytokine Res 2012;32(6):277-9
22. Murdaca G, Colombo BM, Puppo F. The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases. Intern Emerg Med 2011;6(6):487-95
23. Chiang EY, Kolumam GA, Yu X, et al. Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med 2009;15(7):766-73
24. Takemura S, Braun A, Crowson C, et al. Lymphoid neogenesis in rheumatoid synovitis. J Immunol 2001;167:1072-80
25. Bocchino M, Matarese A, Bellofiore B, et al. Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment. Eur J Clin Microbiol Infect Dis 2008;27(10):907-13
26. Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003;48:1667-75
27. Hatemi G, Melikoglu M, Ozbakir F, et al. Quantiferon-TB Gold in tube assay for the screening of tuberculosis before and during treatment with tumor necrosis factor alpha antagonists. Arthritis Res Ther 2012;14(3):R147
28. Murdaca G, Spanò F, Cagnati P, Puppo F. Free radicals and endothelial dysfunction: potential positive effects of TNF-alpha inhibitors. Redox Rep 2013;18(3):95-9
29. Murdaca G, Spanò F, Miglino M, Puppo F. Effects of TNF-alpha inhibitors upon the mechanisms of action of VEGF. Immunotherapy 2013;5(2):113-15
30. Ciprandi G, Murdaca G, Colombo BM, et al. Serum vascular endothelial growth factor in allergic rhinitis and systemic lupus erythematosus. Hum Immunol 2008;69(8):510-12
31. Ciprandi G, Colombo BM, Murdaca G, De Amici M. Serum vascular endothelial growth factor and sublingual immunotherapy. Allergy 2008;63(7):945-6
32. Szekanecz Z, Kerekes G, Soltész P. Vascular effects of biologic agents in RA and spondyloarthropathies. Nat Rev Rheumatol 2009;5(12):677-84
33. Colombo BM, Cacciapaglia F, Puntoni M, et al. Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS Study). Autoimmun Rev 2009;8(4):309-15
34. Colombo BM, Murdaca G, Caiti M, et al. Intima-media thickness: a marker of accelerated atherosclerosis in women with systemic lupus erythematosus. Ann N Y Acad Sci 2007;1108:121-6
35. Murdaca G, Colombo BM, Cagnati P, et al. Endothelial dysfunction in rheumatic autoimmune diseases. Atherosclerosis 2012;224(2):309-17
36. Hyrich KL, Watson KD, Silman AJ, Symmons DP. British Society for Rheumatology Biologics Register. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006;45(12):1558-65
37. Kooloos WM, de Jong DJ, Huizinga TW, Guchelaar HJ. Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease. Drug Discov Today 2007;12(3-4):125-31
38. Breedveld FC, Weisman MH, Kavanaugh AF, et al. For the PREMIER Investigators. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37
39. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81
40. Maini RN, Breedveld FC, Kalden JR, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004;50:1051-65
41. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33
42. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9
43. Emery P, Dorner T. Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response. Ann Rheum Dis 2011;70(12):2063-70
44. Louis E, Franchimont D, Piron A, et al. Tumor necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)- stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998;113:401-6
45. Guis S, Balandraud N, Bouvenot J, et al. Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis. Arthritis Rheum 2007;57(8):1426-30
46. Padyukov L, Lampa J, Heimbürger M, et al. Genetic markers for the efficacy of tumor necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis 2003;62:526-9
47. Seitz M, Wirthmüller U, Moller B, Villiger PM. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNF alphablockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford) 2007;46(1):93-6
48. Maxwell JR, Potter C, Hyrich KL, et al. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet 2008;17(22):3532-8
49. Schmeling H, Horneff G. Tumour necrosis factor alpha promoter polymorphisms and etanercept therapy in juvenile idiopathic arthritis. Rheumatol Int 2007;27(4):383-6
50. Stojanović S, Jevtović-Stoimenov T, Stanković A, et al. [Association of TNFalpha polymorphism (-308 A/G) with high activity of rheumatoid arthritis and therapy response to Etanercept]. Srp Arh Celok Lek 2011;139(11-12):784-9
51. Marotte H, Arnaud B, Diasparra J, et al. Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor. Arthritis Rheum 2008;58(5):1258-63
52. Kang CP, Lee KW, Yoo DH, et al. The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in. rheumatoid arthritis. Rheumatology 2005;44:547-52
53. Schotte H, Schlüter B, Drynda S, et al. Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64(4):575-81
54. Murdaca G, Gulli R, Spanò F, et al. TNF-a Gene Polymorphisms: Association with Disease Susceptibility and Response to Anti-TNF-a Treatment in Psoriatic Arthritis. J Invest Dermatol 2014;134(10):2503-9
55. Morales-Lara MJ, Cañete JD, Torres-Moreno D, et al. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis. Joint Bone Spine 2012;79(6):591-6
56. Pierik M, Vermeire S, Steen KV, et al. Tumour necrosis factor-a receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Aliment Pharmacol Ther 2004;20:303-10
57. Louis EJ, Watier HE, Schreiber S, et al. Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study. Pharmacogenet Genomics 2006;16:911-14
58. Ho P, Bruce IN, Silman A, et al. Evidence forcommongenetic control in pathways of inflammation for Crohn's disease and psoriatic arthritis. Arthritis Rheum 2005;52:3596-602
59. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008;8(1):34-47
60. Bruhns P, Iannascoli B, England P, et al. Specificity and affinity of human Fc gamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009;113(16):3716-25
61. van Sorge NM, van der Pol WL, van deWinkel JG. FcgammaR polymorphisms: implications for function, disease susceptibility and immunotherapy. Tissue Antigens 2003;61(3):189-202
62. Canete JD, Suarez B, Hernandez MV, et al. Influence of variants of Fcgamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumor necrosis alpha therapy in rheumatoid arthritis. Ann Rheum Dis 2009;68(10):1547-52
63. Tutuncu Z, Kavanaugh A, Zvaifler N, et al. Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum 2005;52(9):2693-6
64. Louis E, El Ghoul Z, Vermeire S, et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther 2004;19(5):511-19
65. Julía M, Guilabert A, Lozano F, et al. The role of Fcgamma receptor polymorphisms in the response to anti-tumor necrosis factor therapy in psoriasis A pharmacogenetic study. JAMA Dermatol 2013;149(9):1033-9
66. Fantuzzi F, Del Giglio M, Gisondi P, Girolomoni G. Targeting tumor necrosis factor alpha in psoriasis and psoriatic arthritis. Expert Opin Ther Targets 2008;12(9):1085-96
67. Strange A, Capon F, Spencer CC, et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 2010;42(11):985-90
68. Boyton RJ, Altmann DM. Natural killer cells, killer immunoglobulin-like receptors and human leucocyte antigen class I in disease. Clin Exp Immunol 2007;149:1-8
69. Ryan C, Kelleher J, Fagan MF, et al. Genetic markers of treatment response to tumour necrosis factor-alpha inhibitors in the treatment of psoriasis. Clin Exp Dermatol 2014;39(4):519-24
70. Criswell LA, Lum RF, Turner KN, et al. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum 2004;50:2750-6
71. Potter C, Cordell HJ, Barton A, et al. Association between anti tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa} B signalling pathways. Ann Rheum Dis 2010;69(7):1315-20
72. Jančić I, Arsenović-Ranin N, Sefik-Bukilica M, et al. -174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis. Rheumatol Int 2013;33(6):1481-6
73. Tejasvi T, Stuart PE, Chandran V, et al. TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis. J Invest Dermatol 2012;132(3 Pt 1):593-600
74. Tan RJ, Gibbons LJ, Potter C, et al. Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment. Ann Rheum Dis 2010;69(6):1029-35
75. Cui J, Saevarsdottir S, Thomson B, et al. Rheumatoid arthritis risk allele PTPRC is also associated with response to antitumor necrosis factor alpha therapy. Arthritis Rheum 2010;62(7):1849-61